Vela Diagnostics launches NGS-based pan-cancer panels
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Recommendation is based on pivotal data from the phase III POLARIX study
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
Subscribe To Our Newsletter & Stay Updated